Medicine
Permanent URI for this communityhttp://repository.kln.ac.lk/handle/123456789/12
This repository contains the published and unpublished research of the Faculty of Medicine by the staff members of the faculty
Browse
6 results
Search Results
Item Lymphatic filariasis in the Southeast Asian region; status and control options.(CABI Publishing, 2020) Chandrasena, T.G.A.N.; Premaratna, R.; Mallawarachchi, C.H.; Gunaratna, D.G.A.M.; de Silva, N.R.ABSTRACT: The Global Program to Eliminate Lymphatic Filariasis (GPELF) was launched in year 2000 by the World Health Organization (WHO) with the goal set for elimination by 2020. Over half the global disease burden lies in the Southeast Asian region (SEAR). The preventive chemotherapy (PC) programme has been initiated in all the WHO SEAR member states with varying levels of progress. Maldives, Sri Lanka and Thailand have achieved the goal of elimination as a public health problem (EPHP) within the stipulated period with Bangladesh working towards validation in 2021. Both Sri Lanka and Thailand are continuing with post-validation surveillance combined with selective treatment, striving for zero transmission in-parallel with the morbidity management and disability prevention program (MMDP). Timor-Leste appears close to reaching critical transmission thresholds with 100% coverage and triple therapy in the last round of PC. Data on MMDP activities are insufficient to comment on reaching EPHP status. PC coverage and country reports indicate ongoing transmission in Nepal, Myanmar, Indonesia and India requiring further rounds of PC. The PELF has made considerable progress in the SEAR towards elimination but there still remain significant transmission and disease burden in the highly populated countries in SEAR.Item Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects(Public Library of Science, 2018) Chandrasena, N.; Premaratna, R.; Gunaratne, I.E.; de Silva, N.R.BACKGROUND: Sri Lanka was acknowledged to have eliminated lymphatic filariasis (LF) as a public health problem in 2016, largely due to its success in Mass Drug Administration (MDA) to interrupt disease transmission. Analysis of the Strengths, Weaknesses, Opportunities and Threats (SWOT) of the national Morbidity Management and Disability Prevention (MMDP) program, the other pillar of the LF control program, was carried out with the objective of evaluating it and providing recommendations to optimize the use of available resources. METHODOLOGY: A situation analysis of the MMDP activities provided by the state health sector was carried out using published records, in-depth interviews with key informants of the Anti Filariasis Campaign, site-visits to filariasis clinics with informal discussions with clinic workforce and personal communications to identify strengths and weaknesses; and opportunities to overcome weaknesses and perceived threats to the program were explored. The principal strength of the MMDP program was the filariasis clinics operational in most endemic districts of Sri Lanka, providing free health care and health education to clinic attendees. The weaknesses identified were the low accessibility of clinics, incomplete coverage of the endemic region and lack of facilities for rehabilitation. The perceived threats were diversion of staff and resources for control of other vector-borne infections, under-utilization of clinics and non-compliance with recommended treatment. Enhanced high level commitment for MMDP, wider publicity and referral systems, integration of MMDP with other disease management services and collaboration with welfare organizations and research groups were identified as opportunities to overcome weaknesses and challenges. CONCLUSIONS: The recommended basic package of MMDP was functional in most of the LF-endemic region. The highlighted weaknesses and challenges, unless addressed, may threaten program sustainability. The identified opportunities for improvement of the programme could ensure better attainment of the goal of the MMDP program, namely access to basic care for all affected by lymphatic filarial disease.Item Human infection with sub-periodic Brugia spp. in Gampaha District, Sri Lanka: a threat to filariasis elimination status?(BioMed Central, 2018) Mallawarachchi, C.H.; Chandrasena, T.G.A.N.; Premaratna, R.; Mallawarachchi, S.M.N.S.M.; de Silva, N.R.BACKGROUND: Post-mass drug administration (MDA) surveillance during the lymphatic filariasis (LF) elimination program in Sri Lanka, revealed the re-emergence of brugian filariasis after four decades. This study was done with the objectives of investigating the epidemiology and age-specific vulnerability to infection. Surveillance was done using night blood smears (NBS) and the Brugia rapid test (BRT), to detect microfilaria (MF) and anti-Brugia IgG4 antibodies in blood samples collected from an age-stratified population enrolled from two high-risk study areas (SA)s, Pubudugama and Wedamulla in the Gampaha District. The periodicity of the re-emergent Brugia spp. was characterized by quantitative estimation of MF in blood collected periodically over 24 h using nucleopore-membrane filtration method. RESULTS: Of 994 participants [Pubudugama 467 (47.9%) and Wedamulla 527 (53%)] screened by NBS, two and zero cases were positive for MF at Pubudugama (MF rate, 0.43) and Wedamulla (MF rate, 0), respectively, with an overall MF rate of 0.2. Of the two MF positives, one participant had a W. bancrofti while the other had a Brugia spp. infection. Of 984 valid BRT test readings [Pubudugama (n = 461) and Wedamulla (n = 523)], two and seven were positive for anti-brugia antibodies by BRT at Pubudugama (antibody rate 0.43) and Wedamulla (antibody rate 1.34), respectively, with an overall antibody rate of 0.91. Both MF positives detected from SAs and two of three other Brugia spp. MF positives detected at routine surveillance by the National Anti-Filariasis Campaign (AFC) tested negative by the BRT. Association of Brugia spp. infections with age were not evident due to the low case numbers. MF was observed in the peripheral circulation throughout the day (subperiodic) with peak counts occurring at 21 h indicating nocturnal sub-periodicity. CONCLUSIONS: There is the low-level persistence of bancroftian filariasis and re-emergence of brugian filariasis in the Gampaha District, Sri Lanka. The periodicity pattern of the re-emergent Brugia spp. suggests a zoonotic origin, which causes concern as MDA may not be an effective strategy for control. The importance of continuing surveillance is emphasized in countries that have reached LF elimination targets to sustain programmatic gains.Item Surveillance for transmission of lymphatic filariasis in Colombo and Gampaha districts of Sri Lanka following mass drug administration(Oxford University Press, 2016) Chandrasena, T.G.A.N.; Premaratna, R.; Samarasekera, D.S.; de Silva, N.R.BACKGROUND: Sri Lanka was recently declared by WHO to have eliminated lymphatic filariasis as a public health problem, after conclusion of annual mass drug administration. Our aim was to assess the lymphatic filariasis situation, following mass drug administration. METHODS: Surveillance was done in two districts of the Western Province in two consecutive phases (2009-2010 and 2013-2015), by examining 2461 thick night blood smears and performing 250 dipstick tests on children for antibodies to Brugia malayi. RESULTS AND CONCLUSIONS: Decline in bancroftian microfilaraemia (microfilaria rate 0.32% to zero) supports elimination, but re-emergence of brugian filariasisis (antibody rate, 1.6%; one microfilaria positive) is a cause for concern.Item Filarial dance sign (FDS) in patients with lymphatic filariasis(Sri Lanka Medical Association, 2008) Premaratna, R.; Chandrasena, T.G.A.N.; Gunawardena, N.K.; de Silva, N.R.; de Silva, H.J.BACKGROUND: Lymphatic filariasis causes acute lymphangitis, epididymo-orchi tis hydrocoele, lymphoedema and nocturnal cough. Diagnostic tests based on circulating filarial antigens (CFA) and filarial antibodies (FAT) have limitations in confirming symptomatic filariasis. Filaria dance sign (FDS) demonstrated using soft tissue ultrasonography permits identification of live adult filarial worms in-situ. OBJECTIVES: FDS, CFA and FAT status in patients with clinical features suggestive of lymphatic filariasis. DESIGN, SETTING AND METHODS: Adult males with symptoms suggestive of filarial infection were subjected to scrotal scans using a Toshiba 7.5MHz soft tissue transducer to elicit the FDS. All subjects were screened for CFA and FAT by NOW® Filariasis (Binax Inc. USA) and On-Site Filariasis IgG/IgM Rapid Test (Biotech. Inc. USA) respectively. RESULTS: Forty eight males, mean age 48.5 yrs (SD: 15.2), presenting with lymphoedema of lower limbs (LL, n=29), lower limb cellulitis with lymphangitis (LCL, n=7), hydrocoele (H, n=7), acute epididymo-orchitis (A.EO, n=3), hydrocoele with lower limb lymphoedema (HLL, n=2) and nocturnal-cough (NC, n=9) were studied. FDS was demonstrated in 38(79%); 7 patients with H, 16 with LL, 5 with LCL, AEO 1 and 9 with NC. Six of 41 (14.6%) patients tested for filarial antibodies were positive for filaria-specific IgG; 2 of them were also positive for filaria-specific IgM. Two of the six IgG positives were negative for FDS. The 4 IgG and FDS positives had LCL (n=2), H (n=l) and AEO (n=l). All were CFA negative CONCLUSIONS: Although time consuming, demonstration of FDS by soft tissue ultrasonography can be useful in confirming symptomatic filariasis compared to FAT and CFA.Item Modified Dermatology Life Quality Index as a measure of quality of life in patients with filarial lymphoedema(Oxford University Press, 2007) Chandrasena, T.G.A.N.; Premaratna, R.; Muthugala, M.A.R.V.; Pathmeswaran, A.; de Silva, N.R.The quality of life (QoL) and correlates of the QoL of lymphoedema patients attending filariasis clinics and a hospital outpatient department were studied using a Life Quality Index (LQI) in a region endemic for Bancroftian filariasis in Sri Lanka. The index was derived by modifying a previously validated Dermatology Life Quality Index (DLQI) to focus on the oedematous limb rather than the skin. The index was scored from 0 (normal) to 30 (severely affects QoL). Lymphoedema was graded using criteria recommended by the WHO. Another semi-structured questionnaire was used to assess the patient's socioeconomic status, frequency of acute adenolymphangitis attacks (ADLA) and measures practiced for morbidity control. Ninety-one patients (62 females, 29 males; mean age 50.4 years) were studied. A single lower limb, both lower limbs or a single upper limb were affected in 78 (85.7%), 10 (11.0%) and 3 (3.3%) patients, respectively. The severity of lymphoedema ranged from stage 1 (mild) to stage 6 (severe). The mean LQI was 8.2 (SD 5.2, range 0-20). The modified DLQI scores showed a significant positive correlation with severity of lymphoedema and a negative correlation with age (R=0.59 and R=-0.1, respectively). The frequency of ADLAs correlated with an increased modified DLQI score. Local pain, embarrassment and limitations of physical activities were the most distressing aspects of lymphoedema. Disease severity and early onset lymphoedema were found to be significantly associated with poorer QoL in filarial lymphoedema.